CAS: 1260612-13-2
Marca | Datos del producto | Pureza | Rango de precios | Entrega estimada |
---|---|---|---|---|
4(3H)-Pyrimidinone, 2-[2-[(2S)-2,3-dihydro-2-methyl-1H-indol-1-yl]-2-oxoethyl]-6-(4-morpholinyl)- REF: IN-DA000QW8CAS: 1260612-13-2 | 98% | A consultar | Jue 02 Ene 25 | |
SAR-260301 REF: 3D-KAC61213CAS: 1260612-13-2 | Min. 95% | A consultar | Mié 12 Feb 25 | |
SAR-260301 REF: TM-T16841CAS: 1260612-13-2 | 98.65% | 44,00 €~1.326,00 € | Mié 05 Mar 25 | |
(S)-2-(2-(2-Methylindolin-1-yl)-2-oxoethyl)-6-morpholinopyrimidin-4(3H)-one REF: 10-F497230CAS: 1260612-13-2 | 95.0% | - - - | Producto descatalogado |
4(3H)-Pyrimidinone, 2-[2-[(2S)-2,3-dihydro-2-methyl-1H-indol-1-yl]-2-oxoethyl]-6-(4-morpholinyl)-
CAS:1260612-13-2
Fórmula:
C19H22N4O3
Pureza:
98%
Peso molecular:
354.4030
Ref: IN-DA000QW8
1mg | 107,00 € | ||
5mg | 147,00 € | ||
10mg | 265,00 € | ||
25mg | 593,00 € | ||
50mg | 570,00 € | ||
100mg | A consultar | ||
200mg | A consultar |
Entrega estimada en Estados Unidos, el Jueves 2 de Enero de 2025
SAR-260301
CAS:1260612-13-2
SAR-260301 is a small molecule that inhibits the activation of epidermal growth factor receptor (EGFR), …
Fórmula:
C19H22N4O3
Pureza:
Min. 95%
Peso molecular:
354.4 g/mol
Ref: 3D-KAC61213
25mg | A consultar | ||
50mg | A consultar | ||
100mg | A consultar |
Entrega estimada en Estados Unidos, el Miércoles 12 de Febrero de 2025
SAR-260301
CAS:1260612-13-2
SAR-260301 is an orally available and selective inhibitor of PI3Kβ (IC50: 23 nM).
Fórmula:
C19H22N4O3
Pureza:
98.65%
Forma y color:
Solid
Peso molecular:
354.4
Ref: TM-T16841
2mg | 44,00 € | ||
5mg | 67,00 € | ||
10mg | 89,00 € | ||
25mg | 177,00 € | ||
50mg | 269,00 € | ||
100mg | 378,00 € | ||
200mg | 533,00 € | ||
1mL*10mM (DMSO) | 72,00 € |
Entrega estimada en Estados Unidos, el Miércoles 5 de Marzo de 2025
(S)-2-(2-(2-Methylindolin-1-yl)-2-oxoethyl)-6-morpholinopyrimidin-4(3H)-one
CAS:1260612-13-2
Pureza:
95.0%
Peso molecular:
354.4100036621094
Ref: 10-F497230
1g | Descatalogado | Solicitar información | |
250mg | Descatalogado | Solicitar información |